ALISO VIEJO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc. today announced that a next generation SCOUT® radar localization system is currently undergoing clinical validation and expects to announce its commercial availability in the fourth quarter of this year. This proprietary SCOUT technology will enable unprecedented instant response and real-time distance measurement for localizing non-palpable tumors during breast lesion excision surgery, making it the most advanced localizing system in the industry.

With SCOUT, a highly sophisticated reflector is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide, which transmits 50 million pulses per second, to lock on to the reflector's position. The console delivers instant response feedback when the guide comes in contact with the skin, providing both audible and visual indicators. The next generation SCOUT will measure and display distance in millimeters with ± 1mm accuracy, allowing surgeons to optimize their breast conservation strategies.

SCOUT, an FDA-cleared, non-radioactive, wire-free radar breast tumor localization system, is the world's only technology that utilizes radar in human tissue. Previously published data establish SCOUT as an accurate and reliable method to localize and excise breast lesions. Since its market introduction in 2015, SCOUT has been adopted at over 150 leading medical facilities across the United States and it has been used in more than 15,000 patient procedures to date.
"The goal in breast conservation surgery is to preserve as much healthy breast tissue as possible while removing all detectable cancer cells. For women navigating the often difficult road of breast cancer treatment, every millimeter matters," said Eduardo Chi Sing, Chief Technology Officer of Cianna Medical. "We are excited to provide this important advance in breast tumor localization. Based on performance testing to date, we believe that no other breast tumor localization technology currently on the market provides the level of accuracy attainable with the next generation SCOUT system."

The operational efficiency of SCOUT has also been associated with potential cost savings. Data presented at the 2017 American Society of Breast Surgeons Annual Meeting[1] demonstrated a 29-minute difference in average operating room (OR) start delay times with SCOUT compared with traditional wire localization, a decrease of 72.5 percent (95% CI; p < .001). The study authors suggest that this reduction in OR waiting time could support a cost savings of nearly $2,000 per procedure.

Rad Oncology Homepage